Wei J, et al. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front Immunol. 2022;13:1035276.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301–19.

Article  CAS  PubMed  Google Scholar 

Molloy ME, et al. HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors. Mol Cancer Ther. 2024;23(9):1294–304.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hipp S, et al. A bispecific DLL3/CD3 IgG-like T-cell engaging antibody induces antitumor responses in small cell lung cancer. Clin Cancer Res. 2020;26(19):5258–68.

Article  CAS  PubMed  Google Scholar 

Dhillon S. Tarlatamab: first approval. Drugs. 2024;84(8):995–1003.

Article  CAS  PubMed  Google Scholar 

Giffin MJ, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27(5):1526–37.

Article  CAS  PubMed  Google Scholar 

Tendler S, Rudin CM. Tarlatamab: new star on the horizon for small-cell lung cancer? J Clin Oncol. 2023;41(16):2877–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheridan C. Amgen’s bispecific antibody puffs across finish line. Nat Biotechnol. 2015;33(3):219–21.

Article  CAS  PubMed  Google Scholar 

Dickopf S, Georges GJ, Brinkmann U. Format and geometries matter: structure-based design defines the functionality of bispecific antibodies. Comput Struct Biotechnol J. 2020;18:1221–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choudhuri K, et al. T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand. Nature. 2005;436(7050):578–82.

Article  CAS  PubMed  Google Scholar 

Dustin ML, Chakraborty AK, Shaw AS. Understanding the structure and function of the immunological synapse. Cold Spring Harb Perspect Biol. 2010;2(10):a002311.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9(2):182–212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen SW, Zhang W. Current trends and challenges in the downstream purification of bispecific antibodies. Antib Ther. 2021;4(2):73–88.

CAS  PubMed  PubMed Central  Google Scholar 

Li Q, et al. The downstream purification of bispecific antibodies. Anal Biochem. 2025;696:115692.

Article  CAS  PubMed  Google Scholar 

Chen W, et al. One size does not fit all: navigating the multi-dimensional space to optimize T-cell engaging protein therapeutics. MAbs. 2021;13(1):1871171.

Article  PubMed  PubMed Central  Google Scholar 

Hust M, et al. Single chain fab (scFab) fragment. BMC Biotechnol. 2007;7:14.

Article  PubMed  PubMed Central  Google Scholar 

Suurs FV, et al. Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues. J Nucl Med. 2021;62(12):1797–804.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson ML, et al. Interim results of an ongoing phase 1/2a study of HPN328, a tri-specific, half-life extended, DLL3-targeting, T-cell engager, in patients with small cell lung cancer and other neuroendocrine cancers. J Clin Oncol. 2022;40(16_suppl):8566–8566.

Article  Google Scholar 

Wermke M, et al. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas. Future Oncol. 2022;18(24):2639–49.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study. J Clin Oncol. 2023;41(16):2893–903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beltran H, et al. Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). J Clin Oncol. 2024;42(16_suppl):8090–8090.

Article  Google Scholar 

Wermke M, et al. DAREONTM-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): interim analysis results. J Clin Oncol. 2025;43(16_suppl):8094–8094.

Article  Google Scholar 

Paz-Ares LG, et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). J Clin Oncol. 2023;41(16_suppl):TPS8611–TPS8611.

Article  Google Scholar 

Dingemans A-MC, et al. DeLLphi-301: tarlatamab phase 2 trial in small cell lung cancer (SCLC)—efficacy and safety analyzed by presence of brain metastasis. J Clin Oncol. 2024;42(16_suppl):8015–8015.

Article  Google Scholar